Should we or should we not? Secondary debulking in ovarian cancer

Affiliations

Comment

Debra L Richardson. Lancet Oncol. 2021 Apr.

. 2021 Apr;22(4):412-413.

doi: 10.1016/S1470-2045(21)00024-3. Epub 2021 Mar 8.

¹ University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, OK 73104, USA. Electronic address: debra-richardson@ouhsc.edu.

No abstract available

Comment on

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, Jia H, Huang X, Cai Y, Yin S, Jiang R, Tian W, Gao W, Liu J, Yang H, Cheng X, Zang R. Shi T, et al. Lancet Oncol. 2021 Apr;22(4):439-449. doi: 10.1016/S1470-2045(21)00006-1. Epub 2021 Mar 8. Lancet Oncol. 2021. PMID: 33705695 Clinical Trial.